Active metabolite of oxcarbazepine (Cat. No. 3864). Produces dose-dependent inhibition of glutamatergic excitatory postsynaptic potentials (EPSPs). Displays anticonvulsant activity; exhibits minor potentiation of GABAA receptor currents.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 254.28. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.93 mL||19.66 mL||39.33 mL|
|5 mM||0.79 mL||3.93 mL||7.87 mL|
|10 mM||0.39 mL||1.97 mL||3.93 mL|
|50 mM||0.08 mL||0.39 mL||0.79 mL|
References are publications that support the biological activity of the product.
Calabresi et al (1995) Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. I. Modulation of corticostriatal synaptic transmission. Epilepsia 36 990 PMID: 7555963
Benes et al (1999) Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. J.Med.Chem. 42 2582 PMID: 10411478
Zheng et al (2009) Oxcarbazepine, not its active metabolite, potentiates GABAA activation and aggravates absence seizures. Epilepsia 50 83 PMID: 18717705
If you know of a relevant reference for Licarbazepine, please let us know.
View Related Products by Product Action
Keywords: Licarbazepine, Licarbazepine supplier, antiepileptics, anticonvulsants, anticonvulsives, sodium, channels, voltage-gated, Na+, voltage-dependent, inhibitors, inhibits, NaV, GP47779, GP, 47779, Voltage-gated, Sodium, Channels, 3865, Tocris Bioscience
Citations for Licarbazepine
Citations are publications that use Tocris products.
Currently there are no citations for Licarbazepine. Do you know of a great paper that uses Licarbazepine from Tocris? Please let us know.
Reviews for Licarbazepine
There are currently no reviews for this product. Be the first to review Licarbazepine and earn rewards!
Have you used Licarbazepine?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.